Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid-β

Giuseppe Di Fede, Marcella Catania, Emanuela Maderna, Michela Morbin, Fabio Moda, Laura Colombo, Alessandro Rossi, Alfredo Cagnotto, Tommaso Virgilio, Luisa Palamara, Margherita Ruggerone, Giorgio Giaccone, Ilaria Campagnani, Massimo Costanza, Rosetta Pedotti, Matteo Salvalaglio, Mario Salmona, Fabrizio Tagliavini

Research output: Contribution to journalArticle

Abstract

We developed a novel therapeutic strategy for Alzheimera's disease (AD) exploiting the properties of a natural variant of Amyloid-β (Aβ) carrying the A2V substitution, which protects heterozygous carriers from AD by its ability to interact with wild-type Aβ, hindering conformational changes and assembly thereof. As prototypic compound we designed a six-mer mutated peptide (Aβ1-6A2V), linked to the HIV-related TAT protein, which is widely used for brain delivery and cell membrane penetration of drugs. The resulting molecule [Aβ1-6A2V TAT(D)] revealed strong anti-amyloidogenic effects in vitro and protected human neuroblastoma cells from Aβ toxicity. Preclinical studies in AD mouse models showed that short-term treatment with Aβ1-6A2V TAT(D) inhibits Aβ aggregation and cerebral amyloid deposition, but a long treatment schedule unexpectedly increases amyloid burden, although preventing cognitive deterioration. Our data support the view that the AβA2V-based strategy can be successfully used for the development of treatments for AD, as suggested by the natural protection against the disease in human A2V heterozygous carriers. The undesirable outcome of the prolonged treatment with Aβ1-6A2V TAT(D) was likely due to the TAT intrinsic attitude to increase Aβ production, avidly bind amyloid and boost its seeding activity, warning against the use of the TAT carrier in the design of AD therapeutics.

Original languageEnglish
Article number20949
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - Feb 11 2016

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid-β'. Together they form a unique fingerprint.

  • Cite this

    Di Fede, G., Catania, M., Maderna, E., Morbin, M., Moda, F., Colombo, L., Rossi, A., Cagnotto, A., Virgilio, T., Palamara, L., Ruggerone, M., Giaccone, G., Campagnani, I., Costanza, M., Pedotti, R., Salvalaglio, M., Salmona, M., & Tagliavini, F. (2016). Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid-β. Scientific Reports, 6, [20949]. https://doi.org/10.1038/srep20949